Truist Securities Initiates Coverage On Cano Health with Hold Rating, Announces Price Target of $7
Truist Securities analyst Jailendra Singh initiates coverage on Cano Health (NYSE:CANO) with a Hold rating and announces Price Target of $7.
Truist Securities Initiates Coverage On CareMax with Hold Rating, Announces Price Target of $7.5
Truist Securities analyst Jailendra Singh initiates coverage on CareMax (NASDAQ:CMAX) with a Hold rating and announces Price Target of $7.5.
Truist Securities Initiates Coverage On Teladoc Health with Hold Rating, Announces Price Target of $35
Truist Securities analyst Jailendra Singh initiates coverage on Teladoc Health (NYSE:TDOC) with a Hold rating and announces Price Target of $35.
B of A Securities Initiates Coverage On StepStone Group with Buy Rating, Announces Price Target of $42
B of A Securities analyst Samantha Platt initiates coverage on StepStone Group (NASDAQ:STEP) with a Buy rating and announces Price Target of $42.
Truist Securities Initiates Coverage On Signify Health with Hold Rating, Announces Price Target of $30.5
Truist Securities analyst Jailendra Singh initiates coverage on Signify Health (NYSE:SGFY) with a Hold rating and announces Price Target of $30.5.
Jefferies Assumes Golden Entertainment at Buy, Announces Price Target of $64
Jefferies analyst Cassandra Lee assumes Golden Entertainment (NASDAQ:GDEN) with a Buy rating and announces Price Target of $64.
UBS Initiates Coverage On Icon with Buy Rating, Announces Price Target of $270
UBS analyst John Sourbeer initiates coverage on Icon (NASDAQ:ICLR) with a Buy rating and announces Price Target of $270.
HC Wainwright & Co. Initiates Coverage On ANI Pharmaceuticals with Buy Rating, Announces Price Target of $50
HC Wainwright & Co. analyst Oren Livnat initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy rating and announces Price Target of $50.
Needham Initiates Coverage On Arcutis Biotherapeutics with Buy Rating, Announces Price Target of $46
Needham analyst Serge Belanger initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy rating and announces Price Target of $46.
JonesTrading Initiates Coverage On Fusion Pharmaceuticals with Buy Rating, Announces Price Target of $10
JonesTrading analyst Justin Walsh initiates coverage on Fusion Pharmaceuticals (NASDAQ:FUSN) with a Buy rating and announces Price Target of $10.